How to buy Checkpoint Therapeutics stock (CKPT)

Checkpoint Therapeutics is a biotechnology business based in the US. Checkpoint Therapeutics shares (CKPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.64 – an increase of 1.96% over the previous week. Checkpoint Therapeutics employs 23 staff and has a trailing 12-month revenue of around $78,000.

Our top picks for where to buy Checkpoint Therapeutics stock

Buy Checkpoint Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Checkpoint Therapeutics stock price (NASDAQ: CKPT)

Use our graph to track the performance of CKPT stocks over time.

Checkpoint Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$3.64
52-week range	$1.38 - $4.50
50-day moving average more info button	$3.48
200-day moving average more info button	$2.41
Wall St. target price	$18.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.83

Is it a good time to buy Checkpoint Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Checkpoint Therapeutics price performance over time

Historical closes compared with the close of $3.54 from 2024-12-23

1 week (2024-12-18)	-0.84%
1 month (2024-11-26)	-13.66%
3 months (2024-09-25)	58.04%
6 months (2024-06-25)	69.38%

1 year (2023-12-22)	89.30%
2 years (2022-12-23)	-6.10%
3 years (2021-12-23)	31.2
5 years (2019-12-24)	13.8

Checkpoint Therapeutics financials

Revenue TTM	$78,000
Gross profit TTM	$-48,185,000
Return on assets TTM	-316.7%
Return on equity TTM	-1220.38%
Profit margin	0%
Book value	$-0.47
Market Capitalization more info button	$174.3 million

TTM: trailing 12 months

Checkpoint Therapeutics share dividends

We're not expecting Checkpoint Therapeutics to pay a dividend over the next 12 months.

Have Checkpoint Therapeutics's shares ever split?

Checkpoint Therapeutics's shares were split on a 1:10 basis on 5 December 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Checkpoint Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Checkpoint Therapeutics shares which in turn could have impacted Checkpoint Therapeutics's share price.

Checkpoint Therapeutics share price volatility

Over the last 12 months, Checkpoint Therapeutics's shares have ranged in value from as little as $1.38 up to $4.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Checkpoint Therapeutics's is 1.235. This would suggest that Checkpoint Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Checkpoint Therapeutics overview

Checkpoint Therapeutics, Inc. , a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc. , to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts.

Frequently asked questions

null
What percentage of Checkpoint Therapeutics is owned by insiders or institutions?
Currently 15.519% of Checkpoint Therapeutics shares are held by insiders and 13.914% by institutions. How many people work for Checkpoint Therapeutics?
Latest data suggests 23 work at Checkpoint Therapeutics. When does the fiscal year end for Checkpoint Therapeutics?
Checkpoint Therapeutics's fiscal year ends in December. Where is Checkpoint Therapeutics based?
Checkpoint Therapeutics's address is: 95 Sawyer Road, Waltham, MA, United States, 02453 What is Checkpoint Therapeutics's ISIN number?
Checkpoint Therapeutics's international securities identification number is: US1628281073 What is Checkpoint Therapeutics's CUSIP number?
Checkpoint Therapeutics's Committee on Uniform Securities Identification Procedures number is: 162828107